Page last updated: 2024-10-21

hydroxyindoleacetic acid and Nerve Degeneration

hydroxyindoleacetic acid has been researched along with Nerve Degeneration in 37 studies

(5-hydroxyindol-3-yl)acetic acid : A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5.

Nerve Degeneration: Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.

Research Excerpts

ExcerptRelevanceReference
"Kainic acid (KA) was employed to induce neuronal lesions in the more dorsal striatum, the caudate-putamen (CP)."1.31Lesion of caudate-putamen interneurons with kainic acid alters dopamine and serotonin metabolism in the olfactory tubercle of the rat. ( Cubeddu, LX; Guevara, BH; Hoffmann, IS; Torrico, F, 2002)
"Nicotine is a neuroteratogen that targets synaptic function during critical developmental stages and recent studies indicate that CNS vulnerability extends into adolescence, the time that smoking typically commences."1.31Fetal and adolescent nicotine administration: effects on CNS serotonergic systems. ( Ali, SF; Seidler, FJ; Slikker, W; Slotkin, TA; Xu, Z, 2001)
"Pretreatment with chlormethiazole (100 mg/kg i."1.29Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ('Ecstasy') to rats. ( Green, AR; Hewitt, KE, 1994)
"Dexfenfluramine treatment decreased the density of 5-HT uptake sites in the cortex, labelled with [3H]-citalopram, but this partially recovered towards control values at 60 days."1.29Repeated administration of escalating high doses of dexfenfluramine does not produce morphological evidence for neurotoxicity in the cortex of rats. ( Collins, P; Hindmarsh, JG; Hunt, S; Jenner, P; Rose, S, 1996)
" The neurochemical and histological effects of PCA are very similar to those produced by a large dose of methylamphetamine (MA) in that both drugs are toxic to serotonergic nerve terminals and neuronal perikarya in the somatosensory cortex."1.27Endogenously produced 5,6-dihydroxytryptamine may mediate the neurotoxic effects of para-chloroamphetamine. ( Axt, KJ; Commins, DL; Seiden, LS; Vosmer, G, 1987)

Research

Studies (37)

TimeframeStudies, this research(%)All Research%
pre-199015 (40.54)18.7374
1990's16 (43.24)18.2507
2000's5 (13.51)29.6817
2010's1 (2.70)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Moreira, CG1
Barbiero, JK1
Ariza, D1
Dombrowski, PA1
Sabioni, P1
Bortolanza, M1
Da Cunha, C1
Vital, MA1
Lima, MM1
Ricaurte, GA2
Yuan, J2
Hatzidimitriou, G1
Cord, BJ2
McCann, UD2
Callahan, BT1
Guevara, BH1
Torrico, F1
Hoffmann, IS1
Cubeddu, LX1
Götz, ME1
Malz, CR1
Dirr, A1
Blum, D1
Gsell, W1
Schmidt, S1
Burger, R1
Pohli, S1
Riederer, P2
Staley, NA1
Poleksy, HF1
Bensch, KG1
Björklund, A2
Wiklund, L1
Carruba, MO1
Keller, HH1
Da Prada, M1
Parenti, M1
Tirone, F1
Olgiati, VR1
Groppetti, A1
Johnson, H1
Ulfhake, B1
Dagerlind, A1
Bennett, GW1
Fone, KC1
Hökfelt, T1
Hewitt, KE1
Green, AR6
Hörtnagl, H1
Berger, ML1
Havelec, L1
Hornykiewicz, O2
Colado, MI5
Rose, S1
Hunt, S1
Collins, P1
Hindmarsh, JG1
Jenner, P1
Murray, TK1
Williams, JL1
Misra, A1
Dethy, S1
Manto, M1
Bastianelli, E1
Gangji, V1
Laute, MA1
Goldman, S1
Hildebrand, J1
Zheng, Y1
Laverty, R1
Granados, R3
O'Shea, E3
Esteban, B3
Reynolds, GP1
Dalton, CF1
Tillery, CL1
Mangiarini, L1
Davies, SW1
Bates, GP1
Vollenweider, FX1
Gamma, A1
Liechti, M1
Huber, T1
Xu, Z1
Seidler, FJ1
Ali, SF1
Slikker, W1
Slotkin, TA1
Bowen, DM1
White, P1
Spillane, JA1
Goodhardt, MJ1
Curzon, G1
Iwangoff, P1
Meier-Ruge, W1
Davison, AN1
Klawans, H1
Wuttke, W1
Baumgarten, HG1
Lachenmayer, L1
Fenske, M1
Klemm, HP1
Birkmayer, W1
Danielczyk, W1
Neumayer, E1
Pehek, EA1
Crock, R1
Yamamoto, BK1
Zhou, FC1
Azmitia, EC1
Orer, HS1
Merahi, N1
Nosjean, A1
Fattaccini, CM1
Laguzzi, R1
Scatton, B1
Dennis, T1
L'Heureux, R1
Monfort, JC1
Duyckaerts, C1
Javoy-Agid, F1
Ichikawa, N1
Commins, DL1
Axt, KJ1
Vosmer, G1
Seiden, LS1
Battaglia, G1
Yeh, SY1
De Souza, EB1
Andén, NE1
Carlsson, A1
Lindqvist, M1
Magnusson, T1
Atack, C1
Sharpe, JA1
Rewcastle, NB1
Lloyd, KG1
Hill, M1
Tasker, RR1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Placebo-Controlled Pilot Study in Huntington's Disease (CIT-HD)[NCT00271596]Phase 233 participants (Actual)Interventional2005-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Executive Function Composite Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort.

Full Scale Name: The Executive Composite Score (ECS). Definition: Subscales were averaged to compute this composite total score. The ECS is the weighted average of performance on 6 subtests of executive function, including (1) the Controlled Oral Word Association Test, (2) Symbol Digit Modalities test; (3) Stroop Color Word Test (Interference Trial), (4) Trail Making test (Part B), (5) Letter-Number Sequencing, and (6) Animal Naming. Construct Measured: Thinking tasks involving planning, working memory, attention, problem solving, verbal reasoning, inhibition, mental flexibility, and task switching. ECS Scale Range: The ECS score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance on executive functioning tasks. Change Calculation Details: Compares change in executive functioning performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment

Interventionunits on a scale (Least Squares Mean)
Citalopram0.005
Placebo0.172

Hamilton Rating Scale for Depression Comparing Screening (Intake Visit) to Visit 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Full Scale Name: Hamilton Rating Scale for Depression (HAM-D). Definition: The Hamilton Rating Scale for Depression is a clinician-administered multiple item questionnaire used to provide an indication of depression. Construct Measured: Depression. HAM-D Score Range: Raw scores may range from 0 to 54, where higher scores indicate worsening mood. Change Calculation Details: Compares change in mood from screening (intake visit) to visit 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment

Interventionunits on a scale (Least Squares Mean)
Citalopram-0.67
Placebo1.23

Letter Number Sequencing Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Full Scale Name: Letter Number Sequencing (LNS) subtest from the Wechsler Adult Intelligence Scale (WAIS) third edition. Definition: LNS is a task that requires the reordering of an initially unordered set of letters and numbers. Construct Measured: Working memory. LNS Score Range: Raw scores may range from 0 to 21, where lower scores indicate poorer performance in working memory. Change Calculation Details: Compares change in working memory performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment

Interventionunits on a scale (Least Squares Mean)
Citalopram-0.113
Placebo0.225

Semantic Fluency Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Semantic Fluency Score. Definition: The Semantic Fluency Score is the number of words a person can produce given a category, including naming (1) Animal names, (2) Fruit names, (3) Boy names, (4) Girl names, and (5) Vegetable names. Construct Measured: Working memory and verbal initiation. Scale Range: The Semantic Fluency Score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance on working memory tasks. Change Calculation Details: Compares change in working memory performance from visit 2 (week 0) where patients named fruit names to the weighted average of visits 5 (week 12) & 6 (week 15) where patients named girl names and vegetable names respectively for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment

Interventionunits on a scale (Least Squares Mean)
Citalopram0.386
Placebo0.664

Stroop Interference Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

"Full Scale Name: Stroop Interference subtest from The Stroop Color and Word Test. Definition: Participants are asked to name the ink color in which a word is printed when the word itself (which is irrelevant to the task) is the name of a different color rather than the same color. For example, participants may be asked to say red to the word blue printed in red ink. Constructs Measured: Selective attention, response inhibition, cognitive flexibility, and processing speed. Scale Range: The Stroop Interference score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in attention and processing speed performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) and 6 (week 15) for the citalopram versus placebo cohort." (NCT00271596)
Timeframe: after 15 weeks of treatment

Interventionunits on a scale (Least Squares Mean)
Citalopram-0.256
Placebo-0.046

Subgroup Analysis of the Hamilton Depression Rating Scale Comparing Screening (Intake Visit) to Visit 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Full Scale Name: Hamilton Rating Scale for Depression (HAM-D). Definition: The Hamilton Rating Scale for Depression is a clinician-administered multiple item questionnaire used to provide an indication of depression. Construct Measured: Depression. HAM-D Score Range: Raw scores may range from 0 to 54, where higher scores indicate worsening mood. Change Calculation Details: This analysis was restricted to a subgroup and, accordingly, does not reflect the total number of participants as reported in the Participant Flow. This analysis compares change in mood from screening (intake visit) to visit 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment

Interventionunits on a scale (Least Squares Mean)
Citalopram-0.10
Placebo1.50

Symbol-Digit Modalities Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Full Scale Name: The Symbol Digit Modalities Test (SDMT). Definition: The SDMT screens for organic cerebral dysfunction by having the examinee use a reference key to pair specific numbers with given geometric figures in 90 seconds. Construct Measured: Attention, processing speed, and working memory. SDMT Scale Range: Raw scores may range from 0 to 110, where lower scores indicate poorer performance. Change Calculation Details: Compares change in performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment

Interventionunits on a scale (Least Squares Mean)
Citalopram-0.227
Placebo-0.170

Total Functional Capacity Score Comparing Baseline (Week -4) to Visits 4 (Week 6) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Full Scale Name: The Total Functional Capacity (TFC) subscale from the Unified Huntington's Disease Rating Scale (UHDRS). Definition: The TFC is a score that classifies five stages of Huntington's Disease and five levels of function in the domains of workplace, finances, domestic chores, activities of daily living and requirements for unskilled or skilled care. Construct Measured: Activities of Daily Living. Scale Range: The TFC score ranges from 0 to 13, where lower scores indicate poorer performance in activities of daily living. Change Calculation Details: Compares change in TFC performance from Baseline (week -4) to the weighted average of visits 4 (week 6) and 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment

Interventionunits on a scale (Least Squares Mean)
Citalopram-0.54
Placebo-0.06

Trails B Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

"Full Scale Name: Trail Making Test Part B (TMT-B). Definition: The TMT-B test requires participants to connect-the-dots of 25 consecutive targets on a sheet of paper where the subject alternates between numbers and letters, going in both numerical and alphabetical order. Constructs Measured: Attention, set shifting, and processing speed. Scale range: The TMT-B score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in attention and processing speed performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) and 6 (week 15) for the citalopram versus placebo cohort." (NCT00271596)
Timeframe: after 15 weeks of treatment

Interventionunits on a scale (Least Squares Mean)
Citalopram0.087
Placebo0.405

Verbal Fluency Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Full Scale Name: The Verbal Fluency Score (VFC). Definition: The VFC is the number of words a person can produce given a letter, including (1) Naming words that start with F, A, and S; (2) naming words that start with K, W, and R; (3) naming words that start with V, I, and P; (4) naming words that start with O, G, and B; (5) naming words that start with E, N, and T; and (6) naming words that start with J, C, and S. Construct Measured: Verbal initiation and flexibility. Scale Range: The Verbal Fluency Composite Score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in verbal initiation and flexibility from visit 2 (week 0) where patients named words starting with O, G, and B to the weighted average of visits 5 (week 12) and 6 (week 15) where patients named words starting with E, N, and T, and J, C, and S respectively for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment

Interventionunits on a scale (Least Squares Mean)
Citalopram0.140
Placebo0.071

Reviews

1 review available for hydroxyindoleacetic acid and Nerve Degeneration

ArticleYear
Amine precursors in neurologic disorders and the psychoses.
    Research publications - Association for Research in Nervous and Mental Disease, 1975, Volume: 54

    Topics: Acetylcholine; Corpus Striatum; Dopamine; Homovanillic Acid; Humans; Huntington Disease; Hydroxyindo

1975

Other Studies

36 other studies available for hydroxyindoleacetic acid and Nerve Degeneration

ArticleYear
Behavioral, neurochemical and histological alterations promoted by bilateral intranigral rotenone administration: a new approach for an old neurotoxin.
    Neurotoxicity research, 2012, Volume: 21, Issue:3

    Topics: Animals; Avoidance Learning; Disease Models, Animal; Dopaminergic Neurons; Exploratory Behavior; Hyd

2012
RETRACTED: Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("ecstasy").
    Science (New York, N.Y.), 2002, 09-27, Volume: 297, Issue:5590

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Axons; Brain; Carrier Proteins; Corpus Str

2002
Effect of glucoprivation on serotonin neurotoxicity induced by substituted amphetamines.
    The Journal of pharmacology and experimental therapeutics, 2002, Volume: 303, Issue:2

    Topics: Amphetamines; Animals; Antimetabolites; Biogenic Monoamines; Body Temperature; Carrier Proteins; Deo

2002
Lesion of caudate-putamen interneurons with kainic acid alters dopamine and serotonin metabolism in the olfactory tubercle of the rat.
    Cellular and molecular neurobiology, 2002, Volume: 22, Issue:5-6

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Cell Death; Dopamine; Dose-Response Relat

2002
Brain aging phenomena in migrating sockeye salmon Oncorhynchus nerka nerka.
    Journal of neural transmission (Vienna, Austria : 1996), 2005, Volume: 112, Issue:9

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animal Migration; Animals; Antioxidants; Apoptosis; Brain; Ca

2005
Fine structural and biochemical studies on the malignant ganglioneuroma.
    Journal of neuropathology and experimental neurology, 1967, Volume: 26, Issue:4

    Topics: Adrenal Gland Neoplasms; Child, Preschool; Creatinine; Female; Ganglioneuroma; Humans; Hydroxyindole

1967
Mechanisms of regrowth of the bulbospinal serotonin system following 5,6-dihydroxytryptamine induced axotomy. I. Biochemical correlates.
    Brain research, 1980, Jun-02, Volume: 191, Issue:1

    Topics: 5,6-Dihydroxytryptamine; Animals; Axons; Female; Hydroxyindoleacetic Acid; Medulla Oblongata; Nerve

1980
Long-lasting depletion of spinal cord 5-hydroxytryptamine or catecholamines after intraspinal injection of 5,7-dihydroxytryptamine or 6-hydroxydopamine to newborn rats.
    Neuroscience letters, 1983, Feb-21, Volume: 35, Issue:2

    Topics: 5,7-Dihydroxytryptamine; Animals; Animals, Newborn; Brain; Dihydroxytryptamines; Dopamine; Female; H

1983
Presence of opiate receptors on striatal serotoninergic nerve terminals.
    Brain research, 1983, Dec-05, Volume: 280, Issue:2

    Topics: Animals; Corpus Striatum; Dopamine; Enkephalin, Methionine; Fenfluramine; Hydroxyindoleacetic Acid;

1983
The serotoninergic bulbospinal system and brainstem-spinal cord content of serotonin-, TRH-, and substance P-like immunoreactivity in the aged rat with special reference to the spinal cord motor nucleus.
    Synapse (New York, N.Y.), 1993, Volume: 15, Issue:1

    Topics: Aging; Animals; Aromatic-L-Amino-Acid Decarboxylases; Axons; Brain Stem; Fluorescent Antibody Techni

1993
Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ('Ecstasy') to rats.
    Neuropharmacology, 1994, Volume: 33, Issue:12

    Topics: Animals; Chlormethiazole; Dizocilpine Maleate; Haloperidol; Hydroxyindoleacetic Acid; Male; N-Methyl

1994
Role of glucocorticoids in the cholinergic degeneration in rat hippocampus induced by ethylcholine aziridinium (AF64A).
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 1993, Volume: 13, Issue:7

    Topics: Acetylcholine; Adrenalectomy; Animals; Aziridines; Cerebral Ventricles; Choline; Choline O-Acetyltra

1993
The spin trap reagent alpha-phenyl-N-tert-butyl nitrone prevents 'ecstasy'-induced neurodegeneration of 5-hydroxytryptamine neurones.
    European journal of pharmacology, 1995, Jul-14, Volume: 280, Issue:3

    Topics: Analysis of Variance; Animals; Binding, Competitive; Cerebral Cortex; Cyclic N-Oxides; Free Radicals

1995
Repeated administration of escalating high doses of dexfenfluramine does not produce morphological evidence for neurotoxicity in the cortex of rats.
    Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration, 1996, Volume: 5, Issue:2

    Topics: Animals; Appetite Depressants; Binding Sites; Biomarkers; Cerebral Cortex; Citalopram; Fenfluramine;

1996
The spin trap reagent PBN attenuates degeneration of 5-HT neurones in rat brain induced by p-chloroamphetamine but not fenfluramine.
    Neuropharmacology, 1996, Volume: 35, Issue:11

    Topics: Animals; Body Temperature; Brain; Brain Chemistry; Cyclic N-Oxides; Fenfluramine; Hydroxyindoleaceti

1996
Cerebellar spongiform degeneration induced by acute lithium intoxication in the rat.
    Neuroscience letters, 1997, Mar-07, Volume: 224, Issue:1

    Topics: Acute Disease; Animals; Cerebellar Diseases; Cerebellum; Dopamine; Homovanillic Acid; Hydroxyindolea

1997
Role of brain nitric oxide in (+/-)3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity in rats.
    Brain research, 1998, Jun-08, Volume: 795, Issue:1-2

    Topics: Animals; Body Temperature; Enzyme Activation; Enzyme Inhibitors; Hydroxyindoleacetic Acid; Indazoles

1998
Role of hyperthermia in the protective action of clomethiazole against MDMA ('ecstasy')-induced neurodegeneration, comparison with the novel NMDA channel blocker AR-R15896AR.
    British journal of pharmacology, 1998, Volume: 124, Issue:3

    Topics: Animals; Body Temperature; Brain Chemistry; Chlormethiazole; Excitatory Amino Acid Antagonists; Feve

1998
The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy').
    Neuropharmacology, 1998, Volume: 37, Issue:7

    Topics: Animals; Body Temperature; Brain; Cerebral Cortex; Corpus Striatum; Dose-Response Relationship, Drug

1998
Brain neurotransmitter deficits in mice transgenic for the Huntington's disease mutation.
    Journal of neurochemistry, 1999, Volume: 72, Issue:4

    Topics: Animals; Brain Chemistry; Disease Models, Animal; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid;

1999
In vivo evidence against clomethiazole being neuroprotective against MDMA ('ecstasy')-induced degeneration of rat brain 5-HT nerve terminals by a free radical scavenging mechanism.
    Neuropharmacology, 1999, Volume: 38, Issue:2

    Topics: Animals; Biotransformation; Body Temperature; Brain; Cerebral Cortex; Chlormethiazole; Corpus Striat

1999
Is a single dose of MDMA harmless?
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 1999, Volume: 21, Issue:4

    Topics: Animals; Clinical Trials as Topic; Ethics, Medical; Hallucinogens; Humans; Hydroxyindoleacetic Acid;

1999
Fetal and adolescent nicotine administration: effects on CNS serotonergic systems.
    Brain research, 2001, Sep-28, Volume: 914, Issue:1-2

    Topics: Aging; Animals; Binding Sites; Brain; Carrier Proteins; Embryo, Mammalian; Female; Hydroxyindoleacet

2001
Accelerated ageing or selective neuronal loss as an important cause of dementia?
    Lancet (London, England), 1979, Jan-06, Volume: 1, Issue:8106

    Topics: Aged; Aging; Alzheimer Disease; Atrophy; Caudate Nucleus; Cell Count; Choline O-Acetyltransferase; D

1979
De- and regeneration of brain serotonin neurons following 5,7-dihydroxytryptamine treatment: effects on serum LH, FSH and prolactin levels in male rats.
    Brain research, 1977, Oct-07, Volume: 134, Issue:2

    Topics: 5,6-Dihydroxytryptamine; Animals; Follicle Stimulating Hormone; Hydroxyindoleacetic Acid; Hypothalam

1977
Dopaminergic supersensitivity in parkinsonism.
    Advances in neurology, 1975, Volume: 9

    Topics: Aged; Benzyl Compounds; Brain; Brain Chemistry; Dopamine; Drug Therapy, Combination; Female; Humans;

1975
Selective subregional dopamine depletions in the rat caudate-putamen following nigrostriatal lesions.
    Synapse (New York, N.Y.), 1992, Volume: 10, Issue:4

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Caudate Nucleus; Corpus Striatum; Dopamine; Homovanillic Ac

1992
Neurotrophic factor for serotonergic neurons prevents degeneration of grafted raphe neurons in the cerebellum.
    Brain research, 1990, Jan-22, Volume: 507, Issue:2

    Topics: Animals; Cell Count; Cerebellum; Dose-Response Relationship, Drug; Graft Survival; Hippocampus; Hydr

1990
Cardiovascular effects of the local injection of 5,7-dihydroxytryptamine into the nodose ganglia and nucleus tractus solitarius in awake freely moving rats.
    Brain research, 1991, Jul-05, Volume: 553, Issue:1

    Topics: 5,7-Dihydroxytryptamine; Animals; Blood Pressure; Electrodes, Implanted; Electroencephalography; Ele

1991
Degeneration of noradrenergic and serotonergic but not dopaminergic neurones in the lumbar spinal cord of parkinsonian patients.
    Brain research, 1986, Aug-13, Volume: 380, Issue:1

    Topics: Aged; Dopamine; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Nerve Degeneratio

1986
Study on monoamine metabolite contents of cerebrospinal fluid in patients with neurodegenerative diseases.
    The Tohoku journal of experimental medicine, 1986, Volume: 150, Issue:4

    Topics: Adult; Aged; Female; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methoxyhydr

1986
Endogenously produced 5,6-dihydroxytryptamine may mediate the neurotoxic effects of para-chloroamphetamine.
    Brain research, 1987, Sep-01, Volume: 419, Issue:1-2

    Topics: 5,6-Dihydroxytryptamine; Amphetamines; Animals; Brain Chemistry; Hippocampus; Hydroxyindoleacetic Ac

1987
MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons.
    Pharmacology, biochemistry, and behavior, 1988, Volume: 29, Issue:2

    Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Biological Transport, Active; Brain; Dose-Resp

1988
Effect of acute axotomy (spinal cord transection) on the turnover of 5-hydroxytryptamine.
    Advances in biochemical psychopharmacology, 1974, Volume: 10

    Topics: Acetamides; Amphetamine; Animals; Catechols; Fenclonine; Hallucinogens; Hydroxyindoleacetic Acid; Ly

1974
Effect of acute transection on the synthesis and turnover of 5-HT in the rat spinal cord.
    Naunyn-Schmiedeberg's archives of pharmacology, 1973, Volume: 277, Issue:1

    Topics: 5-Hydroxytryptophan; Animals; Carboxy-Lyases; Cordotomy; Hydroxyindoleacetic Acid; Male; Nerve Degen

1973
Striatonigral degeneration. Response to levodopa therapy with pathological and neurochemical correlation.
    Journal of the neurological sciences, 1973, Volume: 19, Issue:3

    Topics: Basal Ganglia; Carboxy-Lyases; Cerebellum; Cerebral Cortex; Corpus Striatum; Diencephalon; Dihydroxy

1973